Assessment of the safety and efficacy of oral Moxidectin, Synriam®, Synriam®-Praziquantel combination versus Praziquantel in school children infected with Schistosoma haematobium and Schistosoma mansoni

Geigy Foundation0 个研究点目标入组 240 人开始时间: 2015年7月19日最近更新: 2023年8月28日

适应症

试验速览

•1. Written informed consent signed by parents and/or legal guardian, and oral assent by children
•2. Able and willing to be examined by a study physician at the beginning of the study
•3. Able and willing to provide two stool samples, three urine samples and one finger prick test at baselin and approximately three weeks after treatment (follow-up)
•4. Positive for S. mansoni or S. haematobium eggs in the stool and/or in urine
•5. Absence of major systemic illnesses (e.g. cancer, diabetes, clinical malaria or hepato-splenic schistosomiasis) as assessed by a medical doctor, upon initial clinical assessment
•6. No known or reported history of chronic illness, e.g. cancer, diabetes, chronic heart, liver or renal disease
•7. No anthelminthic or antimalarial treatments within past 4 weeks
•8. No known allergy to study medications

•1. No written informed consent by parents and/or legal guardian
•2. Presence of any abnormal medical condition, judged by the study physician.
•3. History of acute or severe chronic disease such as cancer, diabetes, chronic heart, liver or renal disease
•4. Recent use of anthelminthic or antimalarial drugs (within past 4 weeks)
•5. Attending other clinical trials during the study
•6. Negative diagnostic result for S. mansoni or S. haematobium (absence of helminth eggs in stool/urine)

发起方

Geigy Foundation